Amylyx Pharmaceuticals (NASDAQ:AMLX) and Mannatech (NASDAQ:MTEX) Head-To-Head Review

Mannatech (NASDAQ:MTEX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Risk & Volatility

Mannatech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mannatech and Amylyx Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
Amylyx Pharmaceuticals	1	2	9	2	2.86

Amylyx Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 51.45%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Mannatech.

Valuation and Earnings

This table compares Mannatech and Amylyx Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$110.41 million	0.14	$2.49 million	($0.86)	-9.15
Amylyx Pharmaceuticals	$87.37 million	14.32	-$301.74 million	($1.80)	-6.33

Mannatech has higher revenue and earnings than Amylyx Pharmaceuticals. Mannatech is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mannatech and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-1.50%	-22.75%	-4.75%
Amylyx Pharmaceuticals	N/A	-68.95%	-61.52%

Insider & Institutional Ownership

13.0% of Mannatech shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Amylyx Pharmaceuticals beats Mannatech on 8 of the 15 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.